Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 6/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740718 | 1.00 | ACSS2 (0.46) | ACSS2GLP1RHTR7HTR6KDM4E | |
| SCHEMBL29826815 | 0.91 | ACSS2 (0.46) | ACSS2GLP1RHTR7HTR6KDM4E | |
| SCHEMBL30740795 | 0.91 | ACSS2 (0.46) | ACSS2GLP1RHTR7HTR6KDM4E | |
| SCHEMBL29945993 | 0.91 | ACSS2 (0.41) | ACSS2GLP1RHTR7HTR6KDM4E | |
| SCHEMBL22392102 | 0.90 | GLP1R (0.44) | ACSS2GLP1RHTR7HTR6PPARG | |
| SCHEMBL26483189 | 0.89 | GLP1R (0.45) | ACSS2GLP1RPPARG | |
| SCHEMBL31159736 | 0.88 | GLP1R (0.45) | ACSS2GLP1RKDM4EDRD2TBXA2R | |
| SCHEMBL20266537 | 0.88 | GLP1R (0.45) | ACSS2GLP1RKDM4EDRD2TBXA2R | |
| SCHEMBL30020641 | 0.88 | ACSS2 (0.47) | ACSS2GLP1RHTR7HTR6KDM4E | |
| SCHEMBL24900035 | 0.88 | ACSS2 (0.47) | ACSS2GLP1RHTR7HTR6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4461355-A2 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-4373821-A1 | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF | Hepagene Therapeutics (HK) Limited (HK) | 2024-05-29 | — | — | EP | disclosed |
| CN-117715906-A | Glucagon-like peptide-1 receptor modulators and uses thereof | 和博医药有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4334304-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024028795-A1 | HETEROBICYCLIC COMPOUNDS AS ORAL GLP1R AGONISTS | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-02-08 | — | — | WO | disclosed |
| EP-4284795-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-116507326-A | Compounds as GLP-1R agonists | 拓臻制药公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4199919-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023111144-A1 | CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023001237-A1 | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF | Hepagene Therapeutics (HK) Limited (CN) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001237-A1 | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF | Hepagene Therapeutics (HK) Limited (CN) | 2023-01-26 | — | — | WO | disclosed |
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2022235717-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022184849-A1 | GLP-1R AGONISTS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | LES LABORATOIRES SERVIER (FR) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022165076-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| CN-114716423-A | 5, 6-dihydro-1, 2, 4-triazines and their pharmaceutical use as GLP-1 receptor agonists | 中国科学院上海药物研究所 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022040600-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040600-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | ACSS2 1914/4885GLP1R 1/4885HTR7 227/4885 |
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | ACSS2 2389/4885GLP1R 1/4885HTR7 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.